Baidu
map

CSCO 2011:≥4个腋下淋巴结转移乳腺癌患者的局部治疗模式及预后因素分析

2011-09-15 殷文瑾 MedSci原创

  上海复旦大学附属肿瘤医院乳腺外科/乳腺癌研究所 复旦大学上海医学院肿瘤学系 殷文瑾 柳光宇 狄根红 吴炅 沈镇宙 邵志敏 陆劲松   目的:≥4个腋下淋巴结转移的乳腺癌患者具有高危复发风险。大量研究结果已证实,这类患者即使经过积极规范的治疗仍预后较差。然而,目前有关这类患者临床病理学特征的研究却并不多见。因此,本文旨在探究

  上海复旦大学附属肿瘤医院乳腺外科/乳腺癌研究所 复旦大学上海医学院肿瘤学系 殷文瑾 柳光宇 狄根红 吴炅 沈镇宙 邵志敏 陆劲松

  目的:≥4个腋下淋巴结转移的乳腺癌患者具有高危复发风险。大量研究结果已证实,这类患者即使经过积极规范的治疗仍预后较差。然而,目前有关这类患者临床病理学特征的研究却并不多见。因此,本文旨在探究这类乳腺癌患者潜在的预后因子,并明确其有效的治疗模式,以期为临床实践提供借鉴和启发。

  方法:本研究对在我院手术的518例≥4个腋下淋巴结转移的原发性乳腺癌患者进行回顾性分析。采用Kaplan-Meier方法描绘生存曲线,Cox 比例风险模型则用于明确无病生存期(DFS)和总生存期(OS)的独立预测因子。结果:根据腋下淋巴结转移数目,本研究将518例患者分为4-6个淋巴结组(38.22%)和≥7个淋巴结组(61.78%)。与≥7个淋巴结组相比,4-6个淋巴结组的肿块相对较小(P<0.001),且接受改良根治术的患者更为多见(P<0.001)。单因素分析结果发现,接受改良根治术和根治术患者的DFS(P=0.2454)和OS(P=0.6428)无显著性差异。然而,亚组分析观察到,根治术可显著改善≥7个淋巴结转移患者的DFS(P=0.0305),同时OS获益也具有临界统计学意义(P=0.547);相反,根治术却未能显著延长4-6个淋巴结组的DFS(P=0.6217)和OS(P=0.7761)。另外,本研究还发现,术后放疗可明显改善患者的 DFS(P=0.0360),且进一步的亚组分析发现术后放疗获益仅见于≥7个淋巴结组(P=0.0107)而非4-6个淋巴结组(P=0.3344)。

  多因素分析结果显示:腋下淋巴结状态(P=0.001)、肿瘤大小(P=0.005)、术后放疗(P=0.015)和手术方式(P=0.016)是 DFS的独立预测因子;腋下淋巴结状态(P=0.001)、肿瘤大小(P=0.001)和手术方式(P=0.035)同样亦是OS的独立预测因子,而术后放疗则具有临界统计学意义(P=0.099)。

  结论:本研究发现,局部治疗包括手术和放疗可显著改善≥4个尤其是≥7个腋下淋巴结转移的高危乳腺癌患者的预后。因此,对这类患者而言,临床实践中除了应重视辅助全身治疗包括化疗和内分泌治疗之外,局部治疗策略同样不容忽视。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
    2011-09-17 sodoo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
    2011-09-17 chg122
  4. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1292906, encodeId=85d21292906dd, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302481, encodeId=12b0130248175, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405620, encodeId=ad2e140562031, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425807, encodeId=7658142580e5c, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1d3994789, createdName=venlin, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479258, encodeId=4bbd14e925861, content=<a href='/topic/show?id=8c141001e8c6' target=_blank style='color:#2F92EE;'>#预后因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100178, encryptionId=8c141001e8c6, topicName=预后因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49d37510120, createdName=ms2536978994064944, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555133, encodeId=25e2155513340, content=<a href='/topic/show?id=b9c0646602d' target=_blank style='color:#2F92EE;'>#治疗模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64660, encryptionId=b9c0646602d, topicName=治疗模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12b614593183, createdName=yankaienglish, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570869, encodeId=a26015e086932, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 17 08:54:00 CST 2011, time=2011-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3133, encodeId=0f8a313361, content=改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98d945896, createdName=ximengchuixue, createdTime=Thu Sep 15 23:35:00 CST 2011, time=2011-09-15, status=1, ipAttribution=)]
    2011-09-15 ximengchuixue

    改良根治术和根治术患者的预后差别不大,今后可能还是以综合治疗为主

    0

相关资讯

雌激素或决定绝经前乳腺癌预后

 ASCO 2011报道:Recchia等的一项研究报告表明,使用促黄体激素释放激素(LH-RH)类似物行雌激素剥夺治疗,可降低绝经前ER+和ER-高危乳腺癌患者的血浆血管内皮生长因子(VEGF)水平。这些数据显示,通过调节VEGF,雌激素可能是导致绝经前乳腺癌患者预后不良的原因。   从2003年4月至2008年10月,100例绝经期前早期乳腺癌患者被纳入研究。研究在基线、手术后,测定患者血

卵巢切除术后激素替代治疗不增加乳腺癌风险

 宾夕法尼亚大学Abramson癌症中心的Susan M. Domchek博士在美国临床肿瘤学会(ASCO)年会上公布的一项观察性队列研究显示,有BRCA突变并接受了预防性卵巢切除术的女性仍可通过激素替代治疗(HRT)控制围绝经期症状,至少短期治疗不增加乳腺癌风险。 这项名为“外科终点的预防和观察(PROSE)”的研究从美国和欧洲20个中心招募了1,299例存在BRCA1突变(61%)

大于70岁可手术乳腺癌患者可辅助序贯化疗

  《临床乳腺癌》(Clin Breast Cancer)杂志近期发表的一项研究显示,年龄大于70岁的可手术乳腺癌患者接受每周辅助表柔比星联合紫杉醇化疗是可行的。这种疗法的安全性尚可接受,疗效令人鼓舞,应当在老年患者中进行进一步研究。   该研究从2005年到2009年前瞻性地纳入了59 例年龄大于70岁的可手术乳腺癌患者,患者术后接受了每周辅助表柔比星联合紫杉醇化

CSCO 2011:中国大陆早期乳腺癌保乳术后放射治疗的全国调查

 中国医学科学院肿瘤医院 张烨 惠周光 余子豪 李晔雄   目的:全国早期乳腺癌保乳手术的开展逐渐增加,本研究调查2009年度国内保乳术后放射治疗的实际开展情况。   方法:2009年底一份有关保乳术后放射治疗实际开展情况的调查表邮寄至中国大陆的所有登记在中华放射肿瘤学协会的放射治疗单位,对于未回复的单位2010年初再次寄发调查表,并对所有回访的调查表进

TACE联合全身化疗或延长乳腺癌术后肝转移患者生存期

 《癌症研究与临床肿瘤学杂志》(J Cancer Res Clin Oncol)7月26日在线发表的一项研究结果表明,经导管动脉内化疗栓塞(TACE)联合全身化疗(SC)或可延长乳腺癌患者乳房切除术后肝转移者的生存期。   该研究对比了44例接受TACE联合全身化疗的患者(TSC组)和43例接受全身化疗的患者(SC)的转归。   结果显示,从诊断为肝转移

NCCN PK FDA:Avastin治疗乳腺癌的存废之争

今年1月,在专家组全票支持的情况下,FDA撤销了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。而7月30日,NCCN专家组却全票(24票对0票,1票弃权)支持在转移性乳腺癌治疗指南中保留Avastin。各方表现颇值得玩味。 同时欧盟European Medicines Agency(EMA)仍然保持了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。

Baidu
map
Baidu
map
Baidu
map